RCS - EMV Capital PLC - Portfolio Update

EMV CapitalAnnouncement

20/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251120:nRST2656Ia&default-theme=true

RNS Number : 2656I  EMV Capital PLC  20 November 2025

For announcement on Reach: 07:00, 20 November 2025

 

EMV Capital plc

 

("EMVC" or the "Company")

 

Portfolio Update

 

As part of its ongoing investor engagement programme, EMV Capital plc (AIM:
EMVC), the deep tech and life sciences VC investment group, is pleased to
announce that it will host a virtual Meet the Portfolio event on 1 December
2025 at 2.00 p.m. The session will provide investors with greater insight into
two of its portfolio companies, Wanda Health and Deeptech Recycling.

 

Virtual Meet the Portfolio - Wanda Health and DeepTech Recycling

 

The online event will take place via the Investor Meet Company platform and
will be hosted by Dr. Ilian Iliev, CEO of EMV Capital plc, who will be joined
by the CEOs of:

·     Wanda Health (https://emvcapital.com/portfolio/wanda-health/) , the
intelligent platform for Remote Patient Monitoring and Virtual Care; and

·   DeepTech Recycling
(https://emvcapital.com/portfolio/deeptech-recycling/) , the advanced
technology platform transforming unrecyclable plastics into sustainable
resources.

This presentation is open to all interested parties. Anyone can sign up for
free and join the live presentation via:

https://www.investormeetcompany.com/emv-capital-plc/register-investor
(https://www.investormeetcompany.com/emv-capital-plc/register-investor)

 

Those who already follow the Company on the Investor Meet Company platform
will automatically be invited.

 

Questions can be submitted pre-event via your Investor Meet Company dashboard
up until 30 November 2025, 09:00 a.m., or at any time during the live
presentation.

 

In accordance with UK Market Abuse Regulation (UK MAR), no inside information
will be disclosed during the event.

 

-Ends-

 

For more information, please contact:

 EMV Capital plc                                                              via Rosewood

 Ilian Iliev, CEO

 Panmure Liberum Limited (NOMAD and Broker)                                   +44 (0)20 7886 2500

 Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Rosewood (Financial PR)                                                      +44 (0)20 7653 8702
 John West / Llewellyn Angus / Lily Pearce

 

 

About EMV Capital plc (EMVC)

 

EMV Capital plc, is a deep tech and life sciences venture capital investment
group with an international portfolio of high-growth companies.

With a strategic focus on generating superior returns for investors from the
fast-growing sectors and technologies that will define our future; EMV Capital
invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its
portfolio companies, creating an evergreen structure that supports extensive
growth and value creation. EMV Capital's investment thesis is realised through
these capital sources:

·     capital-efficient investments through Group balance sheet;

·     fund management of the Evergreen EIS and Martlet Capital Funds;

·     syndicated investments leveraging its network of third-party
investors.

EMV Capital's approach is characterised by its proactive management style,
aiming to advance portfolio companies to critical value inflection points by
actively engaging with them. Companies are supported through Board
representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international
links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

www.emvcapital.com (http://www.emvcapital.com/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUKUARVVUAAUA



            Copyright 2019 Regulatory News Service, all rights reserved